BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. Source
No articles found.
PLx Pharma Inc. (Nasdaq: PLXP), is a late-stage specialty pharmaceutical company i...
PLx Pharma Inc. (Nasdaq: PLXP), is a late-stage...
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to ...
ImmunoGen is developing the next generation of ...
BrainsWay is an industry leader in the field of transcranial magnetic stimulation ...
BrainsWay is an industry leader in the field of...
The mission of Cassava Sciences is to detect and treat neurodegenerative diseases,...
The mission of Cassava Sciences is to detect an...
Cerecor is an integrated biopharmaceutical company developing innovative therapies...
Cerecor is an integrated biopharmaceutical comp...
We are an international biotechnology company that is focused in the field of rege...
We are an international biotechnology company t...
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company seeking to advance targe...
AVEO Pharmaceuticals, Inc. is a biopharmaceutic...
Join the National Investor Network and get the latest information with your interests in mind.